KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $4.9 billion.

  • Vertex Pharmaceuticals' Cash & Equivalents fell 571.84% to $4.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 billion, marking a year-over-year decrease of 571.84%. This contributed to the annual value of $4.6 billion for FY2024, which is 5593.06% down from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' Cash & Equivalents is $4.9 billion, which was down 571.84% from $5.0 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Cash & Equivalents high stood at $11.1 billion for Q3 2023, and its period low was $4.6 billion during Q4 2024.
  • For the 5-year period, Vertex Pharmaceuticals' Cash & Equivalents averaged around $7.4 billion, with its median value being $6.8 billion (2021).
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Cash & Equivalents soared by 7544.05% in 2021, and later tumbled by 5593.06% in 2024.
  • Vertex Pharmaceuticals' Cash & Equivalents (Quarter) stood at $6.8 billion in 2021, then surged by 54.58% to $10.5 billion in 2022, then dropped by 1.28% to $10.4 billion in 2023, then plummeted by 55.93% to $4.6 billion in 2024, then rose by 8.1% to $4.9 billion in 2025.
  • Its Cash & Equivalents stands at $4.9 billion for Q3 2025, versus $5.0 billion for Q2 2025 and $4.7 billion for Q1 2025.